Home/Pipeline/CAR T-Cell Therapy Program

CAR T-Cell Therapy Program

Relapsed/Refractory Multiple Myeloma

DevelopmentActive

Key Facts

Indication

Relapsed/Refractory Multiple Myeloma

Phase

Development

Status

Active

Company

Dr. Reddy's Laboratories

About Dr. Reddy's Laboratories

Founded in 1984, Dr. Reddy's Laboratories has evolved from an API manufacturer into a global pharmaceutical leader with a mission to accelerate access to affordable and innovative medicines. Its core strategy balances a robust generics and biosimilars business with targeted investments in complex generics, innovative therapies, and strategic partnerships. Key recent achievements include the first-to-market launch of a generic semaglutide injection in India, expansion of its biosimilar portfolio in developed markets, and a stated goal to touch 1.5 billion patient lives by 2030.

View full company profile

Therapeutic Areas

Oncology Metabolic Disorders (Diabetes/Obesity)Immunology Infectious Diseases (HIV)Central Nervous System Gastrointestinal Pain Consumer Health

Other Relapsed/Refractory Multiple Myeloma Drugs

Drug	Company	Phase	Status
Aplidin (plitidepsin)	PharmaMar	Approved (Conditional - AU)	R&D
TECVAYLI + DARZALEX FASPRO	johnson-and-johnson-innovative-medicine	Approved	Approved (FDA Mar 2026)
Linvoseltamab	Regeneron	Phase 3	Active
Blenrep (belantamab mafodotin)	GSK	Phase III	Active
HDP-101	Heidelberg Pharma	Phase I/IIa	Active
inobrodib + Pd (InoPd)	CellCentric	Phase 1/2	Active
CT053	CARsgen Therapeutics	Phase Ib/II	Active
CT059	CARsgen Therapeutics	Phase I	Active
P-BCMA-ALLO1	Poseida Therapeutics	Phase 1	Active (Transferred to Roche)
P-BCMA-101	Poseida Therapeutics	Phase 1/2	Legacy Program
ABBV-383	AbbVie	Phase 1	Active
bri-cel (BAY 2413334)	Bayer	Phase I	Active, recruiting